β1肾上腺素受体与CYP2D6 基因多态性对美托洛尔抗高血压治疗的药代动力学和药效学影响

摘要/Abstract

摘要： 背景: 美托洛尔是临床常用的抗高血压药物,它经由CYP2D6 代谢。CYP2D6 *10 降低CYP2D6 活性, 是中国人群中最为常见的多态性。β1肾上腺素受体为美托洛尔的作用靶标, Ser49Gly 与Gly389Arg 多态性显著改变受体功能。CYP2D6 与β1肾上腺素受体遗传多态性对美托洛尔降压疗效的联合影响仍属未知。目的: 发现与美托洛尔药代动力学与药效动力学相关的基因多态性位点。为提高高血压病的疗效和减少不良反应提供实验依据。方法: 符合WHO/ISH 高血压诊断标准的轻、中度高血压患者125 例, 服用美托洛尔单药治疗12 周, 每四周检测血压。在临床观察疗效的同时, 应用PCRRFLP方法对患者进行CYP2D6 *10 与β1 肾上腺素受体Ser49Gly 和Gly389Arg 基因型分析。同时抽取静脉血5mL, 高效液相色谱-荧光检测法测定患者美托洛尔谷浓度。结果: 美托洛尔谷浓度与CYP2D6*10 基因型显著相关, 并呈基因剂量效应。但高血压患者血压降低程度在CYP2D6 *1 *1 、*1 *10与CYP2D6 *10 *10 组间无差异。Gly49 携带者服用美托洛尔后收缩压与舒张压的降低显著大于Ser49Ser 纯合子;与Gly389 携带者相比, Arg389Arg服用美托洛尔后收缩压与舒张压的降低更为显著,表明Gly49 与Arg389 型受体对美托洛尔治疗有较好的敏感性。结论: CYP2D6 *10 突变显著改变美托洛尔的药代动力学, 但对美托洛尔的降压效果无显著性影响。β1 肾上腺素受体遗传多态性与β 受体阻滞药的降压敏感性有一定相关性。

关键词: CYP2D6, β₁ 肾上腺素受体, 遗传多态性, 原发性高血压, 美托洛尔

Abstract: BACKGROUND: Metoprolol is a selectiveβ₁-Blocker commonly used in essentiaL/hypertension. It is metabolized by CYP2D6.CYP2D6 *10, which was identified to decrease activity of CYP2D6, is the main variance in Chinese population.β1-adrenergic receptor, with Ser49Gly and Gly389Arg polymorphisms, is the target of metoprolol.It was still unknown that whether the CYP2D6 andβ₁-adrenergic receptor had a synergic effect on metoprolol antihypertension therapy. AIM: To clarify the genetic polymorphism associated with metoprolol pharmacokinetics and pharmacodynamics in antihypertension therapy. METHODS: 125 mild-to-med essentiaL/hypertension patients were enrolled in this study.Patients were mono-therapied with metoprolol for 12 weeks.Blood pressure was monitored every 4 weeks.PCR-RFLP method was use to identify CYP2D6 *10 andβ₁-adrenergic receptor Ser49Gly and Gly389Arg polymorphisms.Plasma metoprolol concentration was measured by HPLC- fluorescence detection. RESULTS: Trough blood level (C0)of metoprolol was associated with CYP2D6 *10 variance in a gene-dose-effect manner, whereas the extent of blood pressure decrease was not significant different in CYP2D6 *1 *1, *1 *10 and CYP2D6 *10 *10 patients. After 12 weeks metoprolol therapy, Gly49 carriers had stronger decrease in systolic and diastolic blood pressure than that of Ser49 homozygotes.Similarly, subjects homozygous for Arg389 had stronger decrease in blood pressure than that of Gly389 carriers.CONCLUSION: CYP2D6 *10 variance significantly change the pharmacokinetics of metoprolol, and the genetic polymorphisms of β₁-adrenergic receptorwere associated with the pharmacodynamics of metopolol in antihypertension therapy.

Key words: CYP2D6, β1-adenergic receptor, genetic polymorphism, essentiaL/hypertension, metoprolol

. β₁肾上腺素受体与CYP2D6 基因多态性对美托洛尔抗高血压治疗的药代动力学和药效学影响[J]. 中国临床药理学与治疗学, 2007, 12(10): 1130-1137.

LIU Jie, LIU Zhao-qian, LIU Ying-zi, TAN Zhi-rong, HU Dong-li, LI Zhi, WANG Dan, ZHANG Wei, ZHOU Hong-hao. Effects ofβ₁-adrenergic receptor and CYP2D6 genetic polymorphism on metoprolol pharmacokinetics and pharmacodynamics in antihypertension therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1130-1137.

参考文献

1 Evans WE, Relling MV.Pharmacogenomics:translating functional genomics into rational therapeutics[J].Science, 1999; 286:487-491.
2 EvansWE, Johnson JA.Pharmacogenomics:The inherited basis for interindividual differences in drug response[J].Ann Rev Genomics Hum Genet, 2001;2:9-39.
3 McLeod HL, EvansWE.Pharmacogenomics:unlocking the human genome for better drug therapy[J].Ann Rev Pharmacol Toxicol, 2001;41:101-121.
4 Roses AD.Pharmacogenetics[J].Hum Mol Genet, 2001;10: 2261-2267.
5 Sachidananandam R, Weissman D, Schmidt SC, et al. The International SNP Map Working Group.A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms[J].Nature, 2001;409:928-933.
6 Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus[J].J Natl Cancer Inst, 1999;23:1983-1985.
7 Black AJ, McLeod HL, CapelL/hA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine[J].Ann Intern Med, 1998;129:716-718.
8 Evans WE, Hon YY, Bomgaars L, et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine[J]. J Clin Oncol, 2001;19:2293-2301.
9 Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization[J].N Engl J Med, 2001;14:1030-1035.
10 Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment[J].Nat Genet, 1999;22:168-170.
11 Amadio P Jr, Cummings DM, Amadio PB.β-blocker therapy for hypertension.Considerations in selecting the most appropriate agent[J].PostgradMed, 1987;82:152-159.
12 Venter CP, Joubert PH.Ethnic differences in response toβ₁-adrenoceptor blockade by propranolol[J].J Cardiovasc Pharmacol, 1984;6:361-364.
13 Venter CP, Joubert PH, Strydom WJ.The relevance of ethnic differences in hemodynamic responses to the head-up tilt manoeuvre to clinical pharmacological investigations[J].J Cardiovasc Pharmacol, 1985;7:1009-1010.
14 Zhou HH, Koshakji RP, Silberstein DJ, et al. Racial differences in drug response:altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites[J].N Engl JMed, 1989;320:565-570.
15 Veterans Administration Cooperative Study Group.Antihypertensive agents[J].JAMA, 1982;248:2004-2011.
16 Materson BJ, Reda DJ, CushmanWC, et al. Single-drug therapy for hypertension in men.A comparison of six antihypertensive agents with placebo.The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents[J].N Engl J Med, 1993;328:914-921.
17 LennardMS, Silas JH, Freestone S, et al. Oxidation phenotypr:a major determinant of metoprolol metabolism and response[J].N Engl J Med, 1982, 307:1158-1160.
18 Daly AK.Pharmacogenetics of the cytochromes P450[J].Curr Top Med Chem, 2004;4:1733-1744.
19 Nakamura K, Ariyoshi N, Yokoi T, et al. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability[J].Biochem Biophys Res Commun, 2002;293: 969-973.
20 Garcia-Barcelo M, Chow LY, Chiu HF, et al. Genetic analysis of the CYP2D6 locus in a Hong Kong Chinese population[J]. Clin Chem, 2000;46:18-23.
21 Kirchheiner J, Meineke I, Muller G, et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of Eand Z-doxepin in healthy volunteers[J].Pharmacogenetics, 2002;12:571-580.
22 Ambrosioni E, Bacchelli S, Esposti DD, et al. Beta-blockade in hypertension and congestive heart failure[J].J Cardiovasc Pharmacol, 2001;38 Suppl 3:S25-S31.
23 Deroubaix X, Lins RL, Lens S, et al. Comparative bioavailability of a metoprolol controlled release formulation and a bisoprolol normal release tablet after single oral dose administration in healthy volunteers[J].Int J Clin Pharmacol Ther, 1996;34: 61-70.
24 Wuttke H, Rau T, Heide R, et al. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects [J].Clin Pharmacol Ther, 2002;72:429-437.
25 Turki J, Pak J, Green S, et al. Genetic polymorphisms of the β2-adrenergic receptor in nocturnal and non-nocturnal asthma. Evidence that Gly 16 correlates with the nocturnal phenotype [J].J Clin Invest, 1995;95:1635-1641.
26 Martinez FD, Graves PE, Baldini M, et al. Association between genetic polymorphisms of the β₂-adrenoceptor and response to albuterol in children with and without a history of wheezing[J].J Clin Invest, 1997:100:3184-3188.
27 Reihsaus E, Innis M, MacIntyre N, et al. Mutations in the gene encoding for the β₂ adrenergic receptor in normal and asthmatic subjects[J].Am J Respir Cell Mol Biol, 1993;8:334-339.
28 Bray MS, Krushkal J, Li L, et al. Positional genomic analysis identifies the beta (2)-adrenergic receptor gene as a susceptibility locus for human hypertension[J].Circulation, 2000; 101:2877-2882.
29 Arranz M, Collier D, Sodhi M, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene [J].Lancet, 1995;346:281-282.
30 Arranz MJ, Munro J, Bolonna A, et al. Pharmacogenetic prediction of clozapine response[J].Lancet, 2000;355:1615-1616.

[1]	唐慕菲, 沈芸竹, 张保国. CYP2D6基因多态性对托烷司琼预防化疗所致恶心呕吐效果的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 817-822.
[2]	李玲，赵慧佳，陈彬尧，刘晓红，孙功鹏，郝卓文，范志鹏，乐江，吴建国，叶啟发. CYP2R1的遗传多态性及其个体化治疗应用[J]. 中国临床药理学与治疗学, 2019, 24(9): 1053-1059.
[3]	王恩特，张晓丹，周双，赵侠，周颖, 崔一民. 基因多态性对阿米替林代谢动力学、药效学和不良反应的影响[J]. 中国临床药理学与治疗学, 2019, 24(2): 235-240.
[4]	金岳龙，王林红，朱丽君，梁伟，段滢,杨松，陈燕春，赵祥海，沈冲，姚应水. 一氧化氮合酶基因多态性与常用降压药疗效的关联研究[J]. 中国临床药理学与治疗学, 2017, 22(5): 538-544.
[5]	曾慧，肖兰，易宏辉. HRH1与HRH2受体基因多态性与肥胖以及肥胖相关性状的关联分析[J]. 中国临床药理学与治疗学, 2016, 21(9): 1028-1032.
[6]	郭成贤，王晶，李金高，袁洪，周宏灏，阳国平. 临床药物基因组学应用现状[J]. 中国临床药理学与治疗学, 2016, 21(4): 458-462.
[7]	雷雨燕, 朱刚直, 罗茜, 何丽华, 余鹏, 刘质, 冉黎灵, 余敏, 郭歆, 程泽能. 口服奈必洛尔片在健康人体内的药动学研究[J]. 中国临床药理学与治疗学, 2015, 20(9): 1042-1046.
[8]	王莹莹, 程光华, 濮之晨, 葛俊亮, 谢彦, 陈晓磊. CYP2D6^10和CYP2C19^2基因型多态性与接受他莫昔芬治疗乳腺癌患者生存率的相关性研究[J]. 中国临床药理学与治疗学, 2015, 20(5): 552-556.
[9]	郭道遐, 陈燕春, 王林红, 鲁玮, 沈冲, 杨松, 赵祥海, 金岳龙, 姚应水. 高迁移率族蛋白1基因多态性与中国南方农村常用高血压药物疗效的关系[J]. 中国临床药理学与治疗学, 2014, 19(7): 766-771.
[10]	朱泓霞, 王雪锋, 徐倩. 硝苯地平缓释片分别联用马来酸依那普利片与酒石酸美托洛尔片治疗高危高血压的临床疗效观察[J]. 中国临床药理学与治疗学, 2014, 19(10): 1167-1170.
[11]	陈冰, 蔡卫民, 杨婉花. CYP2D6基因多态性与抗精神病药物的个体化应用[J]. 中国临床药理学与治疗学, 2012, 17(9): 1067-1074.
[12]	尹芳, 李云飞, 黄继汉, 李禄金, 郑青山. 长效降压药动态血压试验设计与定量分析方法实例介绍[J]. 中国临床药理学与治疗学, 2012, 17(6): 666-671.
[13]	熊丹, 熊玉卿. CYP2D6基因多态性及对美托洛尔代谢的影响[J]. 中国临床药理学与治疗学, 2011, 16(9): 1059-1064.
[14]	吴惠子, 刘洁. 乳腺癌的遗传药理学研究进展:内分泌治疗与化疗[J]. 中国临床药理学与治疗学, 2011, 16(3): 334-340.
[15]	徐承华, 杨玉雯, 曹蘅. β₁肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响[J]. 中国临床药理学与治疗学, 2011, 16(12): 1414-1418.

β₁肾上腺素受体与CYP2D6 基因多态性对美托洛尔抗高血压治疗的药代动力学和药效学影响

Effects ofβ₁-adrenergic receptor and CYP2D6 genetic polymorphism on metoprolol pharmacokinetics and pharmacodynamics in antihypertension therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价